Gilead Analysts Boost Their Forecasts After Upbeat Q4 Earnings

NodeGuardian · 2026-02-24T07:32:52+00:00

Gilead Sciences exceeded fourth-quarter earnings expectations due to strong HIV therapy growth and the Yeztugo launch, but issued disappointing guidance for fiscal 2026, leading to a drop in share prices despite analysts maintaining positive ratings.

NodeGuardian

2026-02-24 07:32:52

Abstract generation in progress

Gilead Sciences reported upbeat fourth-quarter earnings, beating consensus estimates for both EPS and revenue, driven by strong growth in its HIV prevention therapies and the launch of Yeztugo. Despite the strong quarterly results, the company issued weaker-than-expected fiscal 2026 guidance, causing its shares to fall in pre-market trading. Following the earnings announcement, several analysts, including Needham, Scotiabank, and Cantor Fitzgerald, reiterated their positive ratings and raised their price targets for Gilead.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.